DSM and Crucell sign licensing agreement with GSK
Pursuant to the terms of the agreement, GSK will research a recombinant protein on the PER.C6 platform. Financial terms of the agreement were not disclosed. Crucell’s PER.C6 technology
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
In the six-week placebo-controlled study, Cognition Pharmaceuticals reported, the active group obtained significantly higher scores on secondary outcome measures of memory and learning, including the brief visuospatial memory
Ligustrazine phosphate injection is used intravenously in hospital for treating ischemic cerebrovascular disease, such as insufficiency of blood-supply, cerebral thrombosis as well as cerebral embolism. Juan Han, chairman